# US 2026/0076925 A1 · Epinephrine formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076925 A1
- Document ID: US20260076925A1
- Status: Published application
- Kind: A1
- Application number: 19/398,226
- Filed: 2025-11-24
- Published: 2026-03-19
- Earliest claimed: 2015-03-13
- Assignees: Ph Health Limited
- Applicants: PH Health Limited
- Inventors: Suketu Sanghvi; Vinayagam Kannan; Matthew Kenney
- Web page: https://patentgrep.com/patent/US20260076925A1

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.

## Claims

### Claim 1

A pre-filled syringe containing a composition, the composition comprising:
epinephrine and/or salts thereof,
a tonicity regulating agent,
a pH raising agent,
an antioxidant comprising methionine,
a pH lowering agent,
a transition metal complexing agent, and
water.

### Claim 2 (depends on 1)

The pre-filled syringe of claim 1, wherein the tonicity regulating agent comprises sodium chloride.

### Claim 3 (depends on 1)

The pre-filled syringe of claim 1, wherein the pH raising agent comprises tartaric acid and sodium hydroxide.

### Claim 4 (depends on 1)

The pre-filled syringe of claim 1, wherein the pH lowering agent comprises hydrochloric acid.

### Claim 5 (depends on 1)

The pre-filled syringe of claim 1, wherein the transition metal complexing agent comprises EDTA.

### Claim 6 (depends on 1)

The pre-filled syringe according to claim 1, wherein the composition comprises about 20% or less total impurities after 1 month of storage in accelerated storage conditions.

### Claim 7 (depends on 1)

The pre-filled syringe according to claim 1, wherein the composition comprises about 20% or less total impurities after 2 months of storage in accelerated storage conditions.

### Claim 8 (depends on 1)

The pre-filled syringe according to claim 1, wherein the composition comprises about 20% or less total impurities after 3 months of storage in accelerated storage conditions.

### Claim 9 (depends on 1)

The pre-filled syringe according to claim 1, wherein the composition comprises about 10% or less total impurities after 1 month of storage in accelerated storage conditions.

### Claim 10 (depends on 1)

The pre-filled syringe according to claim 1, wherein the composition comprises about 10% or less total impurities after 2 months of storage in accelerated storage conditions.

### Claim 11 (depends on 1)

The pre-filled syringe according to claim 1, wherein the composition comprises about 10% or less total impurities after 3 months of storage in accelerated storage conditions.

### Claim 12

A pre-filled syringe containing a composition, the composition comprising:
epinephrine and/or salts thereof,
a tonicity regulating agent comprising sodium chloride,
a pH raising agent comprising tartaric acid and sodium hydroxide,
an antioxidant comprising methionine,
a pH lowering agent comprising hydrochloric acid,
a transition metal complexing agent comprising EDTA, and
water.

### Claim 13 (depends on 12)

The pre-filled syringe according to claim 12, wherein the composition comprises about 20% or less total impurities after 1 month of storage in accelerated storage conditions.

### Claim 14 (depends on 12)

The pre-filled syringe according to claim 12, wherein the composition comprises about 20% or less total impurities after 2 months of storage in accelerated storage conditions.

### Claim 15 (depends on 12)

The pre-filled syringe according to claim 12, wherein the composition comprises about 20% or less total impurities after 3 months of storage in accelerated storage conditions.

### Claim 16 (depends on 12)

The pre-filled syringe according to claim 12, wherein the composition comprises about 10% or less total impurities after 1 month of storage in accelerated storage conditions.

### Claim 17 (depends on 12)

The pre-filled syringe according to claim 12, wherein the composition comprises about 10% or less total impurities after 2 months of storage in accelerated storage conditions.

### Claim 18 (depends on 12)

The pre-filled syringe according to claim 12, wherein the composition comprises about 10% or less total impurities after 3 months of storage in accelerated storage conditions.

### Claim 19 (depends on 12)

The pre-filled syringe according to claim 12, wherein the antioxidant consists of methionine.

### Claim 20

A method comprising filling a syringe with a composition, wherein the composition comprises:
epinephrine and/or salts thereof,
a tonicity regulating agent,
a pH raising agent,
an antioxidant comprising methionine,
a pH lowering agent,
a transition metal complexing agent, and
water.
